Tuesday, December 12, 2017 9:56:21 PM
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS is heading to $1
Made Thousands into Millions..Now in Tens of Millions
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM